Your comment seems to be a bit offfbase. PuraStat has been successfully commercializedin UK and France. Do not know if PuraStat is a 'small potatoes' product, but it is generating revenues.
PuraStat may be primitive relative to AC5 (your basis for characterization?), I have no opinion. I do know that AC5 has not been commercialized in the US despite having marketing authorization for last 13 months (Dec 2018). If AC5 is a leap forward in clinical care, what's holding up the market introduction? PERHAPS introducing an endoscopic hemnostat for GI procedures would be a way to go. As said poreviously, AC5 technology seems to have potential, up to management to do something with it.
News 
Market Data 
Discover 
